Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 183 entries
Sorted by: Best Match Show Resources per page
Erratum to: JAK3-STAT pathway blocking benefits in experimental lupus nephritis.

Arthritis research & therapy

Ripoll È, de Ramon L, Draibe J, Merino A, Bolaños N, Goma M, Cruzado JM, Grinyó JM, Torras J.
PMID: 27368974
Arthritis Res Ther. 2016 Jul 01;18(1):152. doi: 10.1186/s13075-016-1058-2.

No abstract available.

Cite
Ripoll È, de Ramon L, Draibe J, et al. Erratum to: JAK3-STAT pathway blocking benefits in experimental lupus nephritis. Arthritis Res Ther. 2016;18(1):152doi: 10.1186/s13075-016-1058-2.
Ripoll, �. �., de Ramon, L., Draibe, J., Merino, A., Bolaños, N., Goma, M., Cruzado, J. M., Grinyó, J. M., & Torras, J. (2016). Erratum to: JAK3-STAT pathway blocking benefits in experimental lupus nephritis. Arthritis research & therapy, 18(1), 152. https://doi.org/10.1186/s13075-016-1058-2
Ripoll, Èlia, et al. "Erratum to: JAK3-STAT pathway blocking benefits in experimental lupus nephritis." Arthritis research & therapy vol. 18,1 (2016): 152. doi: https://doi.org/10.1186/s13075-016-1058-2
Ripoll È, de Ramon L, Draibe J, Merino A, Bolaños N, Goma M, Cruzado JM, Grinyó JM, Torras J. Erratum to: JAK3-STAT pathway blocking benefits in experimental lupus nephritis. Arthritis Res Ther. 2016 Jul 01;18(1):152. doi: 10.1186/s13075-016-1058-2. PMID: 27368974; PMCID: PMC4930563.
Copy Download .nbib Format: NLM
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.

Arthritis research & therapy

Beukelman T, Xie F, Baddley JW, Chen L, Mannion ML, Saag KG, Zhang J, Curtis JR.
PMID: 27655411
Arthritis Res Ther. 2016 Sep 22;18(1):210. doi: 10.1186/s13075-016-1109-8.

BACKGROUND: In the present study, we compared the incidence of hospitalized infection among children with juvenile idiopathic arthritis (JIA) following initiation of treatment with biologic agents versus methotrexate (MTX).METHODS: We used national Medicaid claims data from 2000 through 2010...

Cite
Beukelman T, Xie F, Baddley JW, et al. The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther. 2016;18(1):210doi: 10.1186/s13075-016-1109-8.
Beukelman, T., Xie, F., Baddley, J. W., Chen, L., Mannion, M. L., Saag, K. G., Zhang, J., & Curtis, J. R. (2016). The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis research & therapy, 18(1), 210. https://doi.org/10.1186/s13075-016-1109-8
Beukelman, Timothy, et al. "The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis." Arthritis research & therapy vol. 18,1 (2016): 210. doi: https://doi.org/10.1186/s13075-016-1109-8
Beukelman T, Xie F, Baddley JW, Chen L, Mannion ML, Saag KG, Zhang J, Curtis JR. The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther. 2016 Sep 22;18(1):210. doi: 10.1186/s13075-016-1109-8. PMID: 27655411; PMCID: PMC5032246.
Copy Download .nbib Format: NLM
Prognostic factors for progression of clinical osteoarthritis of the knee: a systematic review of observational studies.

Arthritis research & therapy

Bastick AN, Runhaar J, Belo JN, Bierma-Zeinstra SM.
PMID: 26050740
Arthritis Res Ther. 2015 Jun 08;17:152. doi: 10.1186/s13075-015-0670-x.

INTRODUCTION: We performed a systematic review of prognostic factors for the progression of symptomatic knee osteoarthritis (OA), defined as increase in pain, decline in physical function or total joint replacement.METHOD: We searched for available observational studies up to January...

Cite
Bastick AN, Runhaar J, Belo JN, et al. Prognostic factors for progression of clinical osteoarthritis of the knee: a systematic review of observational studies. Arthritis Res Ther. 2015;17:152doi: 10.1186/s13075-015-0670-x.
Bastick, A. N., Runhaar, J., Belo, J. N., & Bierma-Zeinstra, S. M. (2015). Prognostic factors for progression of clinical osteoarthritis of the knee: a systematic review of observational studies. Arthritis research & therapy, 17152. https://doi.org/10.1186/s13075-015-0670-x
Bastick, Alex N, et al. "Prognostic factors for progression of clinical osteoarthritis of the knee: a systematic review of observational studies." Arthritis research & therapy vol. 17 (2015): 152. doi: https://doi.org/10.1186/s13075-015-0670-x
Bastick AN, Runhaar J, Belo JN, Bierma-Zeinstra SM. Prognostic factors for progression of clinical osteoarthritis of the knee: a systematic review of observational studies. Arthritis Res Ther. 2015 Jun 08;17:152. doi: 10.1186/s13075-015-0670-x. PMID: 26050740; PMCID: PMC4483213.
Copy Download .nbib Format: NLM
Erratum to: Novel hyaluronic acid-methotrexate conjugate suppresses joint inflammation in the rat knee: efficacy and safety evaluation in two rat arthritis models.

Arthritis research & therapy

Tamura T, Higuchi Y, Kitamura H, Murao N, Saitoh R, Morikawa T, Sato H.
PMID: 27246005
Arthritis Res Ther. 2016 May 31;18(1):121. doi: 10.1186/s13075-016-1029-7.

No abstract available.

Cite
Tamura T, Higuchi Y, Kitamura H, et al. Erratum to: Novel hyaluronic acid-methotrexate conjugate suppresses joint inflammation in the rat knee: efficacy and safety evaluation in two rat arthritis models. Arthritis Res Ther. 2016;18(1):121doi: 10.1186/s13075-016-1029-7.
Tamura, T., Higuchi, Y., Kitamura, H., Murao, N., Saitoh, R., Morikawa, T., & Sato, H. (2016). Erratum to: Novel hyaluronic acid-methotrexate conjugate suppresses joint inflammation in the rat knee: efficacy and safety evaluation in two rat arthritis models. Arthritis research & therapy, 18(1), 121. https://doi.org/10.1186/s13075-016-1029-7
Tamura, Tatsuya, et al. "Erratum to: Novel hyaluronic acid-methotrexate conjugate suppresses joint inflammation in the rat knee: efficacy and safety evaluation in two rat arthritis models." Arthritis research & therapy vol. 18,1 (2016): 121. doi: https://doi.org/10.1186/s13075-016-1029-7
Tamura T, Higuchi Y, Kitamura H, Murao N, Saitoh R, Morikawa T, Sato H. Erratum to: Novel hyaluronic acid-methotrexate conjugate suppresses joint inflammation in the rat knee: efficacy and safety evaluation in two rat arthritis models. Arthritis Res Ther. 2016 May 31;18(1):121. doi: 10.1186/s13075-016-1029-7. PMID: 27246005; PMCID: PMC4888418.
Copy Download .nbib Format: NLM
Citrullination, a possible functional link between susceptibility genes and rheumatoid arthritis.

Arthritis research & therapy

Vossenaar ER, Zendman AJ, Van Venrooij WJ.
PMID: 14979924
Arthritis Res Ther. 2004;6(1):1-5. doi: 10.1186/ar1027. Epub 2003 Nov 25.

Antibodies directed to citrullinated proteins (anti-cyclic citrullinated peptide) are highly specific for rheumatoid arthritis (RA). Recent data suggest that the antibodies may be involved in the disease process of RA and that several RA-associated genetic factors might be functionally...

Cite
Vossenaar ER, Zendman AJ, Van Venrooij WJ. Citrullination, a possible functional link between susceptibility genes and rheumatoid arthritis. Arthritis Res Ther. 2003;6(1):1-5doi: 10.1186/ar1027.
Vossenaar, E. R., Zendman, A. J., & Van Venrooij, W. J. (2004). Citrullination, a possible functional link between susceptibility genes and rheumatoid arthritis. Arthritis research & therapy, 6(1), 1-5. https://doi.org/10.1186/ar1027
Vossenaar, Erik R, et al. "Citrullination, a possible functional link between susceptibility genes and rheumatoid arthritis." Arthritis research & therapy vol. 6,1 (2004): 1-5. doi: https://doi.org/10.1186/ar1027
Vossenaar ER, Zendman AJ, Van Venrooij WJ. Citrullination, a possible functional link between susceptibility genes and rheumatoid arthritis. Arthritis Res Ther. 2004;6(1):1-5. doi: 10.1186/ar1027. Epub 2003 Nov 25. PMID: 14979924; PMCID: PMC400418.
Copy Download .nbib Format: NLM
Chondrocyte response to growth factors is modulated by p38 mitogen-activated protein kinase inhibition.

Arthritis research & therapy

Studer RK, Bergman R, Stubbs T, Decker K.
PMID: 14979938
Arthritis Res Ther. 2004;6(1):R56-R64. doi: 10.1186/ar1022. Epub 2003 Nov 07.

Inhibitors of p38 mitogen-activated protein kinase (MAPK) diminish inflammatory arthritis in experimental animals. This may be effected by diminishing the production of inflammatory mediators, but this kinase is also part of the IL-1 signal pathway in articular chondrocytes. We...

Cite
Studer RK, Bergman R, Stubbs T, et al. Chondrocyte response to growth factors is modulated by p38 mitogen-activated protein kinase inhibition. Arthritis Res Ther. 2003;6(1):R56-R64doi: 10.1186/ar1022.
Studer, R. K., Bergman, R., Stubbs, T., & Decker, K. (2004). Chondrocyte response to growth factors is modulated by p38 mitogen-activated protein kinase inhibition. Arthritis research & therapy, 6(1), R56-R64. https://doi.org/10.1186/ar1022
Studer, Rebecca K, et al. "Chondrocyte response to growth factors is modulated by p38 mitogen-activated protein kinase inhibition." Arthritis research & therapy vol. 6,1 (2004): R56-R64. doi: https://doi.org/10.1186/ar1022
Studer RK, Bergman R, Stubbs T, Decker K. Chondrocyte response to growth factors is modulated by p38 mitogen-activated protein kinase inhibition. Arthritis Res Ther. 2004;6(1):R56-R64. doi: 10.1186/ar1022. Epub 2003 Nov 07. PMID: 14979938; PMCID: PMC400413.
Copy Download .nbib Format: NLM
Proposed methods for reviewing the outcomes of health research: the impact of funding by the UK's 'Arthritis Research Campaign'.

Health research policy and systems

Hanney SR, Grant J, Wooding S, Buxton MJ.
PMID: 15272939
Health Res Policy Syst. 2004 Jul 23;2(1):4. doi: 10.1186/1478-4505-2-4.

BACKGROUND: External and internal factors are increasingly encouraging research funding bodies to demonstrate the outcomes of their research. Traditional methods of assessing research are still important, but can be merged into broader multi-dimensional categorisations of research benefits. The onus...

Cite
Hanney SR, Grant J, Wooding S, et al. Proposed methods for reviewing the outcomes of health research: the impact of funding by the UK's 'Arthritis Research Campaign'. Health Res Policy Syst. 2004;2(1):4doi: 10.1186/1478-4505-2-4.
Hanney, S. R., Grant, J., Wooding, S., & Buxton, M. J. (2004). Proposed methods for reviewing the outcomes of health research: the impact of funding by the UK's 'Arthritis Research Campaign'. Health research policy and systems, 2(1), 4. https://doi.org/10.1186/1478-4505-2-4
Hanney, Stephen R, et al. "Proposed methods for reviewing the outcomes of health research: the impact of funding by the UK's 'Arthritis Research Campaign'." Health research policy and systems vol. 2,1 (2004): 4. doi: https://doi.org/10.1186/1478-4505-2-4
Hanney SR, Grant J, Wooding S, Buxton MJ. Proposed methods for reviewing the outcomes of health research: the impact of funding by the UK's 'Arthritis Research Campaign'. Health Res Policy Syst. 2004 Jul 23;2(1):4. doi: 10.1186/1478-4505-2-4. PMID: 15272939; PMCID: PMC503400.
Copy Download .nbib Format: NLM
Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis.

Arthritis research & therapy

Bode SF, Lehmberg K, Maul-Pavicic A, Vraetz T, Janka G, Stadt UZ, Ehl S.
PMID: 22682420
Arthritis Res Ther. 2012 Jun 08;14(3):213. doi: 10.1186/ar3843.

Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease of severe hyperinflammation caused by uncontrolled proliferation of activated lymphocytes and macrophages secreting high amounts of inflammatory cytokines. It is a frequent manifestation in patients with predisposing genetic defects, but can...

Cite
Bode SF, Lehmberg K, Maul-Pavicic A, et al. Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis. Arthritis Res Ther. 2012;14(3):213doi: 10.1186/ar3843.
Bode, S. F., Lehmberg, K., Maul-Pavicic, A., Vraetz, T., Janka, G., Stadt, U. Z., & Ehl, S. (2012). Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis. Arthritis research & therapy, 14(3), 213. https://doi.org/10.1186/ar3843
Bode, Sebastian Fn, et al. "Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis." Arthritis research & therapy vol. 14,3 (2012): 213. doi: https://doi.org/10.1186/ar3843
Bode SF, Lehmberg K, Maul-Pavicic A, Vraetz T, Janka G, Stadt UZ, Ehl S. Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis. Arthritis Res Ther. 2012 Jun 08;14(3):213. doi: 10.1186/ar3843. PMID: 22682420; PMCID: PMC3446494.
Copy Download .nbib Format: NLM
Correction to: Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis?.

Arthritis research & therapy

Orsolini G, Adami G, Rossini M, Fassio A, Giollo A, Caimmi C, Idolazzi L, Gatti D, Viapiana O.
PMID: 30396370
Arthritis Res Ther. 2018 Nov 05;20(1):248. doi: 10.1186/s13075-018-1753-2.

Following publication of the original article [1], the authors reported a typesetting error.

Cite
Orsolini G, Adami G, Rossini M, et al. Correction to: Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis?. Arthritis Res Ther. 2018;20(1):248doi: 10.1186/s13075-018-1753-2.
Orsolini, G., Adami, G., Rossini, M., Fassio, A., Giollo, A., Caimmi, C., Idolazzi, L., Gatti, D., & Viapiana, O. (2018). Correction to: Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis?. Arthritis research & therapy, 20(1), 248. https://doi.org/10.1186/s13075-018-1753-2
Orsolini, Giovanni, et al. "Correction to: Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis?." Arthritis research & therapy vol. 20,1 (2018): 248. doi: https://doi.org/10.1186/s13075-018-1753-2
Orsolini G, Adami G, Rossini M, Fassio A, Giollo A, Caimmi C, Idolazzi L, Gatti D, Viapiana O. Correction to: Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis?. Arthritis Res Ther. 2018 Nov 05;20(1):248. doi: 10.1186/s13075-018-1753-2. PMID: 30396370; PMCID: PMC6235198.
Copy Download .nbib Format: NLM
Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.

Arthritis research & therapy

Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H.
PMID: 31060597
Arthritis Res Ther. 2019 May 06;21(1):114. doi: 10.1186/s13075-019-1897-8.

Following publication of the original article [1], the authors noticed that two corrections were not implemented during the production process.

Cite
Ebina K, Hashimoto M, Yamamoto W, et al. Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study. Arthritis Res Ther. 2019;21(1):114doi: 10.1186/s13075-019-1897-8.
Ebina, K., Hashimoto, M., Yamamoto, W., Hirano, T., Hara, R., Katayama, M., Onishi, A., Nagai, K., Son, Y., Amuro, H., Yamamoto, K., Maeda, Y., Murata, K., Jinno, S., Takeuchi, T., Hirao, M., Kumanogoh, A., & Yoshikawa, H. (2019). Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study. Arthritis research & therapy, 21(1), 114. https://doi.org/10.1186/s13075-019-1897-8
Ebina, Kosuke, et al. "Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study." Arthritis research & therapy vol. 21,1 (2019): 114. doi: https://doi.org/10.1186/s13075-019-1897-8
Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H. Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study. Arthritis Res Ther. 2019 May 06;21(1):114. doi: 10.1186/s13075-019-1897-8. PMID: 31060597; PMCID: PMC6503435.
Copy Download .nbib Format: NLM
Correction to: Adiponectin aggravates bone erosion by promoting osteopontin production in synovial tissue of rheumatoid arthritis.

Arthritis research & therapy

Qian J, Xu L, Sun X, Wang Y, Xuan W, Zhang Q, Zhao P, Wu Q, Liu R, Che N, Wang F, Tan W, Zhang M.
PMID: 29898766
Arthritis Res Ther. 2018 Jun 13;20(1):125. doi: 10.1186/s13075-018-1641-9.

Unfortunately, after publication of this article [1], it was noticed that the panel for Fig. 4b was inadvertently obscured during the production process. The full, correct Fig. 4 can be seen below and the original article has been corrected...

Cite
Qian J, Xu L, Sun X, et al. Correction to: Adiponectin aggravates bone erosion by promoting osteopontin production in synovial tissue of rheumatoid arthritis. Arthritis Res Ther. 2018;20(1):125doi: 10.1186/s13075-018-1641-9.
Qian, J., Xu, L., Sun, X., Wang, Y., Xuan, W., Zhang, Q., Zhao, P., Wu, Q., Liu, R., Che, N., Wang, F., Tan, W., & Zhang, M. (2018). Correction to: Adiponectin aggravates bone erosion by promoting osteopontin production in synovial tissue of rheumatoid arthritis. Arthritis research & therapy, 20(1), 125. https://doi.org/10.1186/s13075-018-1641-9
Qian, Jie, et al. "Correction to: Adiponectin aggravates bone erosion by promoting osteopontin production in synovial tissue of rheumatoid arthritis." Arthritis research & therapy vol. 20,1 (2018): 125. doi: https://doi.org/10.1186/s13075-018-1641-9
Qian J, Xu L, Sun X, Wang Y, Xuan W, Zhang Q, Zhao P, Wu Q, Liu R, Che N, Wang F, Tan W, Zhang M. Correction to: Adiponectin aggravates bone erosion by promoting osteopontin production in synovial tissue of rheumatoid arthritis. Arthritis Res Ther. 2018 Jun 13;20(1):125. doi: 10.1186/s13075-018-1641-9. PMID: 29898766; PMCID: PMC6001130.
Copy Download .nbib Format: NLM
Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease.

Arthritis research & therapy

Cavalli G, Tomelleri A, De Luca G, Campochiaro C, Dinarello CA, Baldissera E, Dagna L.
PMID: 30803447
Arthritis Res Ther. 2019 Feb 25;21(1):69. doi: 10.1186/s13075-019-1850-x.

Following publication of the original article [1], the authors reported an error in the spelling of Lorenzo Dagna's name.

Cite
Cavalli G, Tomelleri A, De Luca G, et al. Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. Arthritis Res Ther. 2019;21(1):69doi: 10.1186/s13075-019-1850-x.
Cavalli, G., Tomelleri, A., De Luca, G., Campochiaro, C., Dinarello, C. A., Baldissera, E., & Dagna, L. (2019). Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. Arthritis research & therapy, 21(1), 69. https://doi.org/10.1186/s13075-019-1850-x
Cavalli, Giulio, et al. "Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease." Arthritis research & therapy vol. 21,1 (2019): 69. doi: https://doi.org/10.1186/s13075-019-1850-x
Cavalli G, Tomelleri A, De Luca G, Campochiaro C, Dinarello CA, Baldissera E, Dagna L. Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. Arthritis Res Ther. 2019 Feb 25;21(1):69. doi: 10.1186/s13075-019-1850-x. PMID: 30803447; PMCID: PMC6388469.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 183 entries